Dimerix Targets Investor and Partner Engagement at J.P. Morgan Healthcare Conference

An update from Dimerix Limited ( (AU:DXB) ) is now available.

Dimerix Limited has announced that CEO and Managing Director Dr Nina Webster will meet investors and potential partners at the 2026 J.P. Morgan Healthcare Conference in San Francisco, where she plans to provide updates on the company’s global Phase 3 trial of DMX-200 in FSGS kidney disease, its commercial partnering progress, and broader growth strategy. The engagement at a major industry forum underscores Dimerix’s efforts to advance its pivotal ACTION3 Phase 3 study, position DMX-200 for potential marketing approval in a rare kidney disorder with no currently approved targeted therapies in the U.S., and strengthen strategic relationships that could influence future commercialisation and company expansion.

The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.53 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited is an Australian clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, particularly kidney conditions such as Focal Segmental Glomerulosclerosis (FSGS), and respiratory disease. Its lead Phase 3 product candidate, DMX-200, targets FSGS kidney disease in patients already receiving standard-of-care angiotensin II receptor blockers, while a second candidate, DMX-700, is being developed for respiratory indications. Both assets were discovered using the company’s proprietary Receptor-HIT technology platform, which enables rapid screening and identification of new drug opportunities by assessing receptor interactions.

Average Trading Volume: 1,208,860

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$324.2M

See more insights into DXB stock on TipRanks’ Stock Analysis page.